# **Supplement**

### **eMethods**

### PET-based staging systems

 PET-based staging systems were included as non-binary categorical measures of Ab and tau pathology. We included two systems for Ab: a three-stage system 6 developed by Mattsson et al<sup>1</sup> and a four-stage system developed by Collij et al<sup>2</sup>. We 7 included Braak staging for tau<sup>3,4</sup>, including both a three-stage and six-stage version. Each stage in each system was associated with a collection of Freesurfer ROIs (stage composite), as shown in eTable 2, with advancing stages indicating regions where pathology spreads over the disease course.

 The method for Mattsson staging and Braak staging were similar and proceeded as follows. First, an average SUVR was calculated in each stage composite using a volume weighted average of bilateral regions. Next, Gaussian mixture models (GMM) were fit to the distribution of uptake in each stage composite to estimate a binary cutoff for stage positivity (as described in the main text Methods: Image-based biomarker definitions). These cutoffs allowed us to assign binary positivity measures for each subject in each stage composite. Disease stages were then assigned based on individual patterns of positivity: to be assigned a given disease stage, an individual had to exhibit positivity for that stage and all prior ones. In case an individual was positive for a given stage but not all prior stages, they were marked as non-stageable. Individuals could also be assigned stage 0 if they were not positive for pathology in any stage composite.

 Collij staging was slightly different in that positivity for a stage composite was based on being positive for pathology in most ROIs corresponding to a given stage. That is, GMMs were fit to each Freesurfer ROI individually, and positivity for a stage composite was defined by exhibiting supra-threshold uptake in 50% or more of the

 associated ROIs. Disease stage assignment then proceeded in the same manner as for Mattsson and Braak staging (individuals needed to be positive for a given disease stage and all prior stages).

#### Cross-validation experiments

 Cross-validated modeling was implemented in Python (v3.10) using scikit-learn (v1.4.2). For all cross-validation experiments, CDR status was used as a stratifying variable. Random samples were also seeded, such that the individuals of each testing fold were the same across experiments with the same input data. All cross-validation experiments had 10 outer folds and were repeated 10 times to generate 100 out of sample error estimates for each tested model.

 We first ran models for each biomarker separately to assess the predictive value of each included definition. These experiments used a non-nested, 10-fold cross- validation. In each iteration, training data were used to fit linear regressions where PHCGlobal was predicted from a single biomarker and covariates (age, sex, *APOE* E4 positivity). That is, separate models were fit for each biomarker. Biomarker definitions with tunable parameters (Z-scores, GMMs) were also fit with training data. A baseline model was also trained in each iteration which only included covariates as predictors. Trained models were then evaluated on the testing fold data, and the prediction accuracies for each were calculated as root mean squared error (RMSE).

 We next created combinatorial models to test if combination of biomarkers improved prediction accuracy and if models incorporating continuous or non-categorical binary biomarkers outperformed models with binary biomarkers. For these experiments, we used nested cross-validation with 10 outer folds and 5 inner folds. In the inner cross-validation, a model selection procedure was applied to identify the best performing individual predictors (like the non-nested cross-validation experiment 52 described above). Inner training data were used to fit linear models predicting PHC<sub>Global</sub> with single biomarkers plus covariates as predictors. Inner testing data were used to measure the out-of-sample accuracy of these models. We then grouped the models 55 based on the pathology  $(AT(N))$  and variable type (binary/non-binary

 categorical/continuous) and selected the best performing biomarker definitions (lowest average RMSE across 5 test folds). The outer cross-validation was then used for training new linear models which combined the biomarkers selected from the inner cross-validation. eTable 3 shows all the combinatorial linear models that were evaluated in the outer loop using this training scheme.

 We also used support vector machine (SVM) regression to directly predict 62 PHC<sub>Global</sub> from imaging data. SVMs were trained using regional A $\beta$  uptakes, tau uptakes, or gray matter volumes as input features. An additional model combined all these regional imaging features into a multimodal predictive model. SVM training used a nested cross-validation design with 10 outer folds and 5 inner folds. The inner loop 66 was used for hyperparameter tuning for the regularization parameter  $C$ , the kernel, and 67 the kernel coefficient  $\gamma$ . Search spaces were informed by consensus 68 recommendations<sup>5</sup> and from pilot experiments: kernel (linear or radial basis function 69 [RBF]), C with linear kernel  $(2^{-10}, 2^{-9}, ..., 2^{-1}, 2^{0})$ , C with RBF kernel 70  $(2^{-5}, 2^{-3}, \cdots, 2^{13}, 2^{15})$ ,  $\gamma$  with RBF kernel  $(2^{-15}, 2^{-13}, \cdots, 2^{1}, 2^{3})$ . The best

hyperparameters were determined from the inner loop (lowest average RMSE across 5

test folds) and used to retrain and evaluate SVM models in the outer loop.

### Feature importance analyses

 We ran additional post-hoc analyses to probe feature importance for our cross- validated linear modeling. For models which applied a model selection to filter biomarker definitions, we created pie charts showing the specific biomarker definitions which were selected as the best performing over repeated cross-validation iterations. 78 We also extracted and plotted the (standardized) linear model coefficients for the  $\mathsf{A}\beta$ , tau, and neurodegeneration biomarkers in all binary and all continuous models (non- binary categorical models were omitted because coefficient interpretation is less straightforward for non-binary categorical features). Finally, we visualized the cutoff 82 values that were selected for A $\beta$  and tau from models with all binary definitions.

 For SVM models, we visualized the feature importance of individual brain regions for A $\beta$ , tau, and neurodegeneration features. Following previous work<sup>6,7</sup>, feature

importance values were generated by calculating the covariance of each feature and

86 PHC<sub>Global</sub>. We generated brain maps showing the average feature importance across

100 out-of-sample model predictions. Maps were generated for the combined SVM and

for each unimodal SVM.

# <sup>90</sup> **eTables**





- 92 models.
- 93
- 94
- 95
- 96
- 97
- 
- 98
- 99
- 100
- 101
- 
- 102
- 103
- 104
- 
- 105
- 106
- 107

![](_page_6_Picture_231.jpeg)

108 **eTable 2.** List of Freesurfer regions used for composite regions. Citations are included 109 for papers which defined these composites. For Collij stging composites, regions 109 for papers which defined these composites. For Collij stging composites, regions<br>110 shown joined by plus signs are meta-ROIs constructed prior to averaging for the

shown joined by plus signs are meta-ROIs constructed prior to averaging for the

111 composite, as described in the original paper<sup>2</sup>. A $\beta$ =amyloid-beta, MT=meta-temporal,

112 ROI=region of interest.

113

114

115

116

117

118

119

120

121

![](_page_7_Picture_281.jpeg)

**eTable 3.** List of linear models predicting PHC<sub>Global</sub> from AT(N) biomarkers. Models were trained with a nested-cross validation scheme where the inner loop was used to were trained with a nested-cross validation scheme where the inner loop was used to

125 select the best performing biomarkers, after grouping by pathology  $(A\beta, \text{tau})$ ,

126 neurodegeneration) and variable type. BIN, CAT, and CON are used to represent

127 binary, non-binary categorical, and continuous variables (respectively). Dashes are

128 shown to indicate omission of the corresponding biomarker in the model. All models

129 also had age, sex, and *APOE* E4 status included as covariates.

130 131

132

133

134

135

136

137

138

139

![](_page_8_Picture_177.jpeg)

![](_page_9_Picture_99.jpeg)

166 **eTable 5:** Characteristics for the subsample with imaging and CSF biomarker 166 **eTable 5:** Cha<br>167 assessments.

168

## **eFigures**

![](_page_10_Figure_1.jpeg)

 **eFigure 1:** Comparison of partial volume corrected (PVC) and non-PVC tau predictors for modeling cognition. **A.** Boxplots of cross-validated accuracy (RMSE) for models including a single tau predictor and covariates. **B.** Boxplots of cross-validated accuracy (RMSE) for models with the best selected tau predictors. Solid colors indicate models without tau PVC, while hatches indicate models with tau PVC. In both panels, the baseline model (just covariates) is shown in gray, with the dotted line indicating its mean performance. Gold stars indicate a significant improvement in accuracy relative to the baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). No significant differences were found 180 for comparisons of PVC and non-PVC models (all p>0.05).

![](_page_11_Figure_0.jpeg)

184 **eFigure 2:** Regional weights for SVM models which included only Aβ (A, A<sub>SVM</sub>), tau (B, 185 T<sub>SVM</sub>), or gray matter volume (C, N<sub>SVM</sub>).

186

187

188

189

190

- 191
- 192

193

194

![](_page_12_Figure_0.jpeg)

 **eFigure 3**: Boxplots showing cross-validated accuracy (RMSE) measures for predicting PHCGlobal in CU (**A**) and CI (**B**) individuals. Individual and combination biomarker models are compared against a baseline model using only covariates (mean 200 performance indicated by dotted line) to predict PHC<sub>Global.</sub> Colors are used to indicate the variable type of included biomarkers (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single 203 pathology assessment, while darker coloring indicates models which have  $A\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 

- 
- 
- 
- 
- 

![](_page_13_Figure_0.jpeg)

 **eFigure 4**: Boxplots showing cross-validated accuracy (RMSE) measures for predicting PHCGlobal in CU (**A**) and CI (**B**) individuals. Combination biomarker models with non- binary variable types are compared against a baseline model with binary biomarker definitions (mean performance indicated by dotted line). Colors are used to indicated the variable type of included biomarkers (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single 220 pathology assessment, while darker coloring indicates models which have  $A\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the baseline model (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 

- 
- 
- 
- 
- 
- 
- 

![](_page_14_Figure_0.jpeg)

 **eFigure 5**: Results from experiments predicting the longitudinal change in PHCGlobal. **A.** Individual and combination biomarker models are compared against a baseline model using only covariates (mean performance indicated by dotted line). **B.** Combination biomarker models with non-binary variable types are compared against a baseline model with binary biomarker definitions (mean performance indicated by dotted line). In both panels, colors are used to indicate the variable type of included biomarkers (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single pathology assessment, while darker coloring indicates models which have A $\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the topmost model. Gray stars and bars highlight significant pairwise differences between individual models. Statistical results are derived from Nadeau-Bengio t-tests with correction for multiple comparisons (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). 

- 
- 
- 
- 

![](_page_15_Figure_0.jpeg)

 **eFigure 6**: Boxplots showing cross-validated accuracy estimates (RMSE) for models 251 predicting neuropsychological performance from biomarkers. Panels show experiments<br>252 using memory (A), executive functioning (B), language (C), and visuospatial (D) using memory (A), executive functioning (B), language (C), and visuospatial (D) composites from the PHC as dependent variables. Combination biomarker models with non-binary variable types are compared against a baseline model with binary biomarker definitions (mean performance indicated by dotted line). In all panels, colors are used to indicate the variable type of included ATN biomarkers (yellow: binary, purple: non- binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which only have a single pathology assessment, while darker coloring indicates models which have A $\beta$ , tau, and neurodegeneration biomarkers. Gold stars indicate a significant improvement in accuracy relative to the topmost model.

![](_page_16_Figure_0.jpeg)

![](_page_16_Figure_1.jpeg)

 **eFigure 7**: Alternate version of main text Figure 1 including CSF predictors alongside imaging-based ones.

- 
- 
- 
- 
- 
- 

### **eReferences**

- 1. Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. *JAMA Neurology*. 2019;76(11):1319-1329. doi:10.1001/jamaneurol.2019.2214
- 2. Collij LE, Heeman F, Salvadó G, et al. Multitracer model for staging cortical amyloid deposition using PET imaging. *Neurology*. 2020;95(11):e1538-e1553. doi:10.1212/WNL.0000000000010256
- 3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259. doi:10.1007/BF00308809
- 4. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol*. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z
- 5. Hsu CW, Chang CC, Lin CJ. A Practical Guide to Support Vector Classification. Published online 2003. https://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf
- 6. Haufe S, Meinecke F, Görgen K, et al. On the interpretation of weight vectors of linear models in multivariate neuroimaging. *NeuroImage*. 2014;87:96-110. doi:10.1016/j.neuroimage.2013.10.067
- 7. Chen J, Ooi LQR, Tan TWK, et al. Relationship between prediction accuracy and feature importance reliability: An empirical and theoretical study. *Neuroimage*. 2023;274:120115. doi:10.1016/j.neuroimage.2023.120115
- 8. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1- 15.e1-4. doi:10.1016/j.jalz.2014.07.003
- 9. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. *Annals of Neurology*. 2012;72(4):578-586. doi:10.1002/ana.23650
- 10. Su Y, Flores S, Wang G, et al. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimers Dement (Amst)*. 2019;11:180-190. doi:10.1016/j.dadm.2018.12.008
- 11. Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut-points for brain aging and Alzheimer's disease. *Alzheimers Dement*. 2017;13(3):205-216. doi:10.1016/j.jalz.2016.08.005
- 12. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain*. 2009;132(Pt 5):1310-1323. doi:10.1093/brain/awn320
- 13. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. *Neurology*. 2009;73(15):1193-1199. doi:10.1212/WNL.0b013e3181bc010c
- 14. Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. *Nat Aging*. 2022;2(6):526-535. doi:10.1038/s43587-022-00204-0
- 15. Pascoal TA, Therriault J, Benedet AL, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. *Brain*. 2020;143(9):2818-2830. doi:10.1093/brain/awaa180
-